Download PDF
Thromb Haemost 2017; 117(12): 2356-2368
DOI: 10.1160/TH17-04-0254
Endothelium and Angiogenesis
Schattauer GmbH Stuttgart

Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry

Artur M. Burylo
,
Vincent A. de Weger
,
Frederik E. Stuurman
,
Jos H. Beijnen
,
Jan H. M. Schellens
Further Information

Publication History

14 April 2017

07 September 2017

Publication Date:
06 December 2017 (online)

    Permissions and Reprints

Abstract

Background Circulating endothelial cells (CECs) are a potential biomarker of angiogenesis. CECs increase in numbers after vessel injury. Higher CEC numbers are reported in cancer patients. Most methods for CEC detection and enumeration rely on flow cytometry (FCM); however, there is no agreement on CEC phenotype and the detection method to be used. This leads to uncertainty about the clinical applicability and variation between studies on CEC numbers reported.

Objective To develop a selective and accurate method for CEC enumeration in peripheral blood by enrichment, followed by FCM in healthy volunteers (HV) and cancer patients.

Methods Samples were enriched using CD34 microbeads, stained with nuclear dye and anti-CD14, CD15, CD45, CD34 and CD146 antibodies. Putative CECs were examined for Weibel–Palade bodies (WPBs) using anti–von Willebrand factor (vWF) antibody and fluorescence microscopy. Linear range of detection (R 2), recovery and precision (coefficient of variation percentage [CV%]) were defined in three experiments by spiking a known number (range 12–12,800 CECs/4 mL) of surrogate endothelial cells in peripheral blood. Sample storage was determined at –80°C for up to 2 months.

Results Sorted CECs showed vWF in the WPBs. The relationship between spiked and detected surrogate cells was R 2 = 1.0, recovery of 94.0 to 101.4% and CV% of 1.0 to 18.4%. Recovery ± standard deviation (within-run days 1, 2 and 3) were, respectively, 102.5% ± 8.2, 97.8% ± 4.6, 99.1% ± 7.7, and after 2 months 94.3% ± 15.3. The median CECs/mL in patients was 24.1 versus 14.4 in HVs.

Conclusion This method for selective, sensitive and reliable CEC analysis by FCM allows for investigation of CECs as a biomarker in clinical research.

Keywords

circulating endothelial cells - enrichment - CD34 magnetic microbeads - flow cytometry - angiogenesis

Supplementary Material

 

  • References

  • 1 Ronzoni M, Manzoni M, Mariucci S. , et al. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol 2010; 21 (12) 2382-2389
    CrossrefPubMedGoogle Scholar
  • 2 Blann AD, Balakrishnan B, Shantsila E, Ryan P, Lip GY. Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers. Prostate 2011; 71 (10) 1047-1053
    CrossrefPubMedGoogle Scholar
  • 3 Goon PK, Boos CJ, Stonelake PS, Blann AD, Lip GY. Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: a methodological comparison. Thromb Haemost 2006; 96 (01) 45-52
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Malka D, Boige V, Jacques N. , et al. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol 2012; 23 (04) 919-927
    CrossrefPubMedGoogle Scholar
  • 5 Ramcharan KS, Lip GY, Stonelake PS, Blann AD. Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome. Int J Colorectal Dis 2015; 30 (03) 315-321
    CrossrefPubMedGoogle Scholar
  • 6 Matsusaka S, Suenaga M, Mishima Y. , et al. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol 2011; 68 (03) 763-768
    CrossrefPubMedGoogle Scholar
  • 7 Jacques N, Vimond N, Conforti R. , et al. Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay. J Immunol Methods 2008; 337 (02) 132-143
    CrossrefPubMedGoogle Scholar
  • 8 Mancuso P, Antoniotti P, Quarna J. , et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 2009; 15 (01) 267-273
    CrossrefPubMedGoogle Scholar
  • 9 Rowand JL, Martin G, Doyle GV. , et al. Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 2007; 71 (02) 105-113
    PubMedGoogle Scholar
  • 10 Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004; 15 (01) 139-145
    CrossrefPubMedGoogle Scholar
  • 11 Calleri A, Bono A, Bagnardi V. , et al. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 2009; 15 (24) 7652-7657
    CrossrefPubMedGoogle Scholar
  • 12 Manzoni M, Mariucci S, Delfanti S. , et al. Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer. J Cancer Res Clin Oncol 2012; 138 (07) 1187-1196
    CrossrefPubMedGoogle Scholar
  • 13 Gari M. Identification of circulating endothelial cells in peripheral blood. Res J Med Sci 2011; 5: 262-268
    PubMedGoogle Scholar
  • 14 Clarke LA, Shah V, Arrigoni F. , et al. Quantitative detection of circulating endothelial cells in vasculitis: comparison of flow cytometry and immunomagnetic bead extraction. J Thromb Haemost 2008; 6 (06) 1025-1032
    CrossrefPubMedGoogle Scholar
  • 15 Delorme B, Basire A, Gentile C. , et al. Presence of endothelial progenitor cells, distinct from mature endothelial cells, within human CD146+ blood cells. Thromb Haemost 2005; 94 (06) 1270-1279
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Mund JA, Estes ML, Yoder MC, Ingram Jr DA, Case J. Flow cytometric identification and functional characterization of immature and mature circulating endothelial cells. Arterioscler Thromb Vasc Biol 2012; 32 (04) 1045-1053
    CrossrefPubMedGoogle Scholar
  • 17 Widemann A, Sabatier F, Arnaud L. , et al. CD146-based immunomagnetic enrichment followed by multiparameter flow cytometry: a new approach to counting circulating endothelial cells. J Thromb Haemost 2008; 6 (05) 869-876
    CrossrefPubMedGoogle Scholar
  • 18 Woywodt A, Goldberg C, Scheer J, Regelsberger H, Haller H, Haubitz M. An improved assay for enumeration of circulating endothelial cells. Ann Hematol 2004; 83 (08) 491-494
    PubMedGoogle Scholar
  • 19 Strijbos MH, Kraan J, den Bakker MA, Lambrecht BN, Sleijfer S, Gratama JW. Cells meeting our immunophenotypic criteria of endothelial cells are large platelets. Cytometry B Clin Cytom 2007; 72 (02) 86-93
    PubMedGoogle Scholar
  • 20 Duda DG, Cohen KS, Scadden DT, Jain RK. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2007; 2 (04) 805-810
    CrossrefPubMedGoogle Scholar
  • 21 Wang Z, Yan X. CD146, a multi-functional molecule beyond adhesion. Cancer Lett 2013; 330 (02) 150-162
    CrossrefPubMedGoogle Scholar
  • 22 Bardin N, Anfosso F, Massé JM. , et al. Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 2001; 98 (13) 3677-3684
    CrossrefPubMedGoogle Scholar
  • 23 Manning T, Smoller BR, Horn TD. , et al. Evaluation of anti-thrombomodulin antibody as a tumor marker for vascular neoplasms. J Cutan Pathol 2004; 31 (10) 652-656
    CrossrefPubMedGoogle Scholar
  • 24 Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem 2006; 54 (04) 385-395
    CrossrefPubMedGoogle Scholar
  • 25 Radecke CE, Warrick AE, Singh GD, Rogers JH, Simon SI, Armstrong EJ. Coronary artery endothelial cells and microparticles increase expression of VCAM-1 in myocardial infarction. Thromb Haemost 2015; 113 (03) 605-616
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Müller AM, Nesslinger M, Skipka G, Müller KM. Expression of CD34 in pulmonary endothelial cells in vivo. Pathobiology 2002; 70 (01) 11-17
    CrossrefPubMedGoogle Scholar
  • 27 Filali EE, Hiralall JK, van Veen HA, Stolz DB, Seppen J. Human liver endothelial cells, but not macrovascular or microvascular endothelial cells, engraft in the mouse liver. Cell Transplant 2013; 22 (10) 1801-1811
    CrossrefPubMedGoogle Scholar
  • 28 Madonna R, Renna FV, Lanuti P. , et al. The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy. PLoS One 2017; 12 (04) e0172800
    CrossrefPubMedGoogle Scholar
  • 29 Dimitriou H, Vorgia P, Stiakaki E. , et al. In vitro proliferative and differentiating characteristics of CD133(+) and CD34(+) cord blood cells in the presence of thrombopoietin (TPO) or erythropoietin (EPO). Potential implications for hematopoietic cell transplantation. Leuk Res 2003; 27 (12) 1143-1151
    CrossrefPubMedGoogle Scholar
  • 30 Pelagiadis I, Relakis K, Kalmanti L, Dimitriou H. CD133 immunomagnetic separation: effectiveness of the method for CD133(+) isolation from umbilical cord blood. Cytotherapy 2012; 14 (06) 701-706
    CrossrefPubMedGoogle Scholar
  • 31 Pluim D, Devriese LA, Beijnen JH, Schellens JH. Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells. Cytometry A 2012; 81 (08) 664-671
    PubMedGoogle Scholar
  • 32 Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 2011; 9: 12
    CrossrefPubMedGoogle Scholar
  • 33 Chong P-P, Selvaratnam L, Abbas AA, Kamarul T. Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cells. J Orthop Res 2012; 30 (04) 634-642
    CrossrefPubMedGoogle Scholar
  • 34 Damani S, Bacconi A, Libiger O. , et al. Characterization of circulating endothelial cells in acute myocardial infarction. Sci Transl Med 2012; 4 (126) 126ra33
    CrossrefPubMedGoogle Scholar
  • 35 Kraan J, Strijbos MH, Sieuwerts AM. , et al. A new approach for rapid and reliable enumeration of circulating endothelial cells in patients. J Thromb Haemost 2012; 10 (05) 931-939
    CrossrefPubMedGoogle Scholar
  • 36 Model MA. Possible causes of apoptotic volume decrease: an attempt at quantitative review. Am J Physiol Cell Physiol 2014; 306 (05) C417-C424
    CrossrefPubMedGoogle Scholar
  • 37 Atkin-Smith GK, Poon IKH. Disassembly of the dying: mechanisms and functions. Trends Cell Biol 2017; 27 (02) 151-162
    CrossrefPubMedGoogle Scholar
  • 38 Mariucci S, Rovati B, Chatzileontiadou S. , et al. A six-colour flow cytometric method for simultaneous detection of cell phenotype and apoptosis of circulating endothelial cells. Scand J Clin Lab Invest 2009; 69 (03) 433-438
    CrossrefPubMedGoogle Scholar
  • 39 Cuppini L, Calleri A, Bruzzone MG. , et al. Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One 2013; 8 (09) e74345
    CrossrefPubMedGoogle Scholar
  • 40 Beije N, Kraan J, Taal W. , et al. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. Br J Cancer 2015; 113 (02) 226-231
    CrossrefPubMedGoogle Scholar
  • 41 Grievink HW, Luisman T, Kluft C, Moerland M, Malone KE. Comparison of three isolation techniques for human peripheral blood mononuclear cells: cell recovery and viability, population composition, and cell functionality. Biopreserv Biobank 2016; 14 (05) 410-415
    CrossrefPubMedGoogle Scholar
  • 42 Nilsson C, Aboud S, Karlén K, Hejdeman B, Urassa W, Biberfeld G. Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects. Clin Vaccine Immunol 2008; 15 (04) 585-589
    CrossrefPubMedGoogle Scholar
  • 43 Paprocka M, Kieda C, Kantor A. , et al. Increased endothelial progenitor cell number in early stage of endometrial cancer. Int J Gynecol Cancer 2017; 27 (05) 947-952
    CrossrefPubMedGoogle Scholar
  • 44 Yuan DM, Zhang Q, Lv YL. , et al. Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients. Tumour Biol 2015; 36 (11) 9031-9037
    CrossrefPubMedGoogle Scholar
  • 45 Kuo Y-H, Lin C-H, Shau W-Y. , et al. Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. BMC Cancer 2012; 12: 620
    CrossrefPubMedGoogle Scholar
  • 46 Rahbari NN, Schölch S, Bork U. , et al. Prognostic value of circulating endothelial cells in metastatic colorectal cancer. Oncotarget 2017; 8 (23) 37491-37501
    CrossrefPubMedGoogle Scholar
  • 47 Kraan J, van den Broek P, Verhoef C. , et al. Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells. Br J Cancer 2014; 111 (01) 149-156
    CrossrefPubMedGoogle Scholar
  • 48 Mehran R, Nilsson M, Khajavi M. , et al. Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res 2014; 74 (10) 2731-2741
    CrossrefPubMedGoogle Scholar
  • 49 Schnegg CI, Yang MH, Ghosh SK, Hsu MY. Induction of vasculogenic mimicry overrides VEGF-A silencing and enriches stem-like cancer cells in melanoma. Cancer Res 2015; 75 (08) 1682-1690
    CrossrefPubMedGoogle Scholar